GlassScriptPhysician profile
Kimberly Morrison
NPI 1609938166
$3,999.42
in general payments reported to CMS, 2019-2025
24 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $962 · 2023: $1,031 · 2024: $797 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.49 | 2022-2025 | Lynparza, Datroway |
| Novocure INC. | $336.27 | 2023-2025 | Optune Lua (Novottf-200t) |
| Seagen INC. | $299.12 | 2021-2023 | Tivdak |
| Merck Sharp & Dohme LLC | $259.30 | 2022-2025 | Keytruda, Lynparza |
| Incyte Corporation | $258.76 | 2022-2025 | Jakafi |
| Servier Pharmaceuticals LLC | $213.10 | 2024 | |
| Gilead Sciences, INC. | $212.00 | 2022-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $176.90 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $169.91 | 2022-2025 | |
| Eisai INC. | $158.53 | 2022-2023 | |
| Genentech USA, INC. | $147.47 | 2022-2025 | Phesgo |
| Daiichi Sankyo INC. | $141.68 | 2024 | Enhertu |
| Stemline Therapeutics INC. | $124.97 | 2025 | Orserdu |
| Mirati Therapeutics, INC. | $122.05 | 2023 | Krazati |
| Emd Serono, INC. | $122.01 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $121.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2025 | Alunbrig |
| Blueprint Medicines Corporation | $121.82 | 2023 | Ayvakit |
| Sobi, INC | $119.25 | 2023 | |
| Celgene Corporation | $111.53 | 2021 | |
| Kite Pharma, INC. | $94.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.70 | 2023 | |
| Myriad Genetic Laboratories, INC. | $21.77 | 2023 | Precisetumor |
| Caris Mpi, INC. | $17.54 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.